SEC Tracker
Get the app

Celcuity CELC

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2

Form
8-K/A
Filed
Importance
Routine
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Celcuity files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Fortrea Holdings FTRE public float $448M, Jun 30, 2025
  2. Castle Biosciences CSTL public float $576M, Jun 30, 2025
  3. Personalis PSNL public float $578M, Jun 30, 2025
  4. Fulgent Genetics FLGT public float $284M, Jun 30, 2025
  5. CareDx CDNA public float $1.0B, Jun 30, 2025